Neuromodulation to Facilitate the Effect of Ketamine (TMS/ketamine)

March 20, 2013 updated by: The Neuroscience Center, LLC

Treatment of Thalamocortical Dysrhythmia Using External Neuromodulation to Facilitate the Therapeutic Effect of Ketamine.

application of external neuromodulation along with ketamine infusion.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

apply TMS concurrent with ketamine infusion in order to increase the likliehood & strength of therapeutic benefit

Study Type

Observational

Enrollment (Actual)

35

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Illinois
      • Deerfield, Illinois, United States, 60015
        • The Neuroscience Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

patients within my own clinic, suffering with chronic emotional and/or somatic pain

Description

Inclusion Criteria:

  • chronically ill,
  • treatment-resistant

Exclusion Criteria:

  • active psychosis

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
chronic depression and/or pain
co-administration of TMS and infused ketamine for patients with chronic pain of psyche and/or soma
Other: co-administration of TMS and infused ketamine
co-administration of TMS and infused ketamine

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Global Assessment of Function in DSM-4R
Time Frame: up to 3 years
treat in order to cause remission of disability
up to 3 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

The Neuroscience Center, LLC

Investigators

  • Principal Investigator: Steven R Devore Best, M.D., The Neuroscience Center

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2011

Primary Completion (Actual)

November 1, 2012

Study Completion (Actual)

November 1, 2012

Study Registration Dates

First Submitted

March 11, 2013

First Submitted That Met QC Criteria

March 20, 2013

First Posted (Estimate)

March 22, 2013

Study Record Updates

Last Update Posted (Estimate)

March 22, 2013

Last Update Submitted That Met QC Criteria

March 20, 2013

Last Verified

March 1, 2013

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 12_1293

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Depression

Clinical Trials on co-administration of TMS and infused ketamine

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Venezuela

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe